BAX and Parkinson disease: In a cellular model of Parkinson’s disease-SH-SY5Y cells treated with MPTP-ASX enhanced cellular function possibly by a mechanism involving the increased expression of antioxidant enzymes (SOD, catalase) and anti-apoptotic proteins (BcL2), as well as decreased expression of the pro-apoptotic protein Bax [46].